Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers

Area of Science:

• Oncology
• Gastroenterology
• Molecular Pathology

Background:

• CDX2 and SATB2 are established biomarkers for determining colorectal adenocarcinoma origin.
• Loss of CDX2 or SATB2 expression is linked to poorer outcomes in colorectal cancer (CRC).
• The prognostic significance of combined CDX2 and SATB2 loss in CRC remains under-investigated.

Purpose of the Study:

• To investigate the clinicopathological features and prognostic value of concomitant CDX2 and SATB2 loss in stage III colorectal cancer.
• To correlate CDX2/SATB2 expression status with molecular alterations and patient survival.

Main Methods:

• Analysis of 431 stage III colorectal cancers using tissue microarray-based immunohistochemistry for CDX2 and SATB2 expression.
• Correlation of biomarker expression with clinicopathological variables, molecular subtypes (CIMP, MSI), and BRAF mutation status.
• Survival analysis to assess the prognostic impact of CDX2 and SATB2 expression patterns.

Main Results:

• CDX2-negative and SATB2-negative (CDX2-/SATB2-) CRCs constituted 3.2% of the cohort.
• Concomitant loss of CDX2 and SATB2 (CDX2-/SATB2-) was significantly associated with poor prognosis in stage III CRC.
• CDX2-/SATB2- CRCs showed associations with right colon tumors, poor differentiation, altered CK20/CK7 expression, CIMP-high, MSI-high, and BRAF mutations.

Conclusions:

• Concomitant loss of CDX2 and SATB2 serves as a significant negative prognostic biomarker in stage III colorectal cancer.
• Isolated loss of CDX2 or SATB2 expression alone is not a prognostic indicator for stage III CRC.
• These findings highlight the importance of dual biomarker assessment for risk stratification in colorectal cancer.